Suppr超能文献

[关于显微镜下结肠炎的观念演变]

[Evolution of ideas on microscopic colitis].

作者信息

Maev I V, Kucheryavyi Yu A, Andreev D N, Cheremushkin S V

机构信息

A.I. Evdokimov Moscow State University of Medicine and Dentistry, Ministry of Health of Russia, Moscow, Russia.

出版信息

Ter Arkh. 2015;87(4):69-76. doi: 10.17116/terarkh201587469-76.

Abstract

The literature review gives the present-day views of the definition, etiology, pathogenesis, diagnosis, and treatment of microscopic colitis (MC). In the present view, MC is an inflammatory bowel disease of unknown etiology, which is characterized by chronic watery diarrhea, no macroscopic signs of large bowel involvement in the presence of specific pathomorphological changes. There are two major forms of MC, which are similar in its clinical picture, yet, heterogeneous in histological criteria: collagenous colitis (CC) and lymphocytic colitis (LC). As of now, the prevalence of MC is about 100 cases per 100,000 population, which is similar with that in other inflammatory bowel diseases, such as ulcerative colitis and Crohn's disease. MC generally prevails in women aged over 50 years. The etiology and pathogenesis of MC have not fully investigated. Watery diarrhea is as a predominant pathognomonic symptom in all the patients with MC. The major histological criterion for the diagnosis of CC is subepithelial collagen lining thickening (more than 10 pm) and that for LC is higher intraepithelial lymphocyte counts (more than 20 intraepithelial lymphocytes/100 epitheliocytes). The topical glucocorticosteroid budesonide is currently the only agent, the efficacy of which has been proven in both inducing and maintaining remission in patients with MC in many clinical trials.

摘要

文献综述阐述了目前关于显微镜下结肠炎(MC)的定义、病因、发病机制、诊断及治疗的观点。目前认为,MC是一种病因不明的炎症性肠病,其特征为慢性水样腹泻,在存在特定病理形态学改变时无大肠受累的宏观体征。MC主要有两种类型,它们在临床表现上相似,但在组织学标准上存在异质性:胶原性结肠炎(CC)和淋巴细胞性结肠炎(LC)。目前,MC的患病率约为每10万人中有100例,这与其他炎症性肠病如溃疡性结肠炎和克罗恩病相似。MC通常在50岁以上的女性中更为常见。MC的病因和发病机制尚未完全明确。水样腹泻是所有MC患者的主要特征性症状。CC诊断的主要组织学标准是上皮下胶原层增厚(超过10μm),LC的主要组织学标准是上皮内淋巴细胞计数增加(每100个上皮细胞中上皮内淋巴细胞超过20个)。局部糖皮质激素布地奈德是目前唯一一种在许多临床试验中已被证实对诱导和维持MC患者缓解均有效的药物。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验